HTA
Introduction MORSE Consulting is pleased to contribute its pCPA/public payer expertise with leading pricing and reimbursement experts and provide our respective views on how the new PMPRB regulations may impact the Canadian environment. These experts include: PMPRB: Joan McCormick, Principal Consultant - IQVIA HTA/Health Economics (HE): Sumeet Singh & Heather Cameron – Cornerstone Research Group Inc. Private Payers: Suzanne Lepage, Suzanne Lepage Consulting The purpose of this summary is two-fold:…
MORSE Consulting summary of CADTH update. On July 31, 2019 CADTH released its Pharmaceutical Reviews Update – Issue 9 and MORSE Consulting has prepared a brief summary of the important developments from this CADTH update. Consultations (Feedback to be provided by September 13, 2019) CADTH is inviting stakeholder comments and feedback on three proposals for the Pharmaceutical Review Programs. 1) Enhance the Transparency of CADTH’s Review Reports and Recommendations…
MORSE Consulting is pleased to release a new report entitled Spotlight on the Atlantic Provinces: pCPA Letter of Intent Conversion and Time-to-Listing Analysis. While the majority of Canadians have some form of prescription medication coverage, the speed and extent to which individual patients gain access to new therapies, can vary significantly. As new drugs (and expanded indications for existing drugs) are approved by Health Canada and become available for use…
Summary of Expensive Drugs for Rare Diseases (EDRD) Working Group Webinar Signals Decoded: Stakeholder consultation is underway on a supplemental process for complex/specialized drugs that builds upon the existing national HTA and reimbursement process to make responsive funding decisions with a focus on non-oncology therapies. The supplemental process is a significant development in EDRD policy and it looks to streamline the evaluation and reimbursement process of eligible drugs…
Panel 5: Patient Support Programs Panel Description: This session will help participants develop a better understanding of why PSPs are well-suited to support the development of outcomes-based agreements. It will suggest effective ways that PSPs can be developed to support data collection for HTA. Finally, current pCPA perspectives on PSPs and the opportunity for data collection within programs will be explored by this panel. Moderator: Allison Wills Panellists: Sang…
HTA Panel – CAHR Market Access 201: Flying Blind – Navigating Patient Access through Uncertainty
Panel 3: Health Technology Assessment Panel Description: Canada’s centralized HTA agency, CADTH, has recently released a new 3-year strategic plan that marks a shift from its previous vision. Noteworthy is the focus of recommendations on alignment of drug assessment with the priorities of the participating plans over all phases of the technology life cycle. Join us to hear CADTH describe their new strategic plan, how their mandate has evolved,…
On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists. According to CADTH’s communication, the objectives of the pilot project are to: Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists.…
A Comparison of Proposed INESSS and Current CADTH Evaluation Fees On February 21, 2018, the Quebec government released draft regulations (Gazette Officielle du Québec) that outline fees payable to Institut national d'excellence en santé et en services sociaux (INESSS) for the scientific evaluation of a drug or stable blood product. The fees are expected to vary based on the type of dossier submitted for scientific review with INESSS determining…
Toronto, February 7, 2018: Cornerstone Research Group and MORSE Consulting are pleased to announce the creation of a strategic partnership between our two organizations. This strategic partnership will simplify the logistical process for our clients utilizing our combined services when shepherding a product from reimbursement strategy, to CADTH submission and finally to pCPA negotiations. Together the collaboration between Cornerstone and MORSE offers clients a breadth of reimbursement consulting services…
Mani & O’Quinn Reimbursement Strategy Experts (MORSE) Consulting Inc. is pleased to introduce MORSE LINKS, a new feature on our website. MORSE LINKS provides a comprehensive list of useful web links which can allow market access professionals to easily access frequently referenced web sites. Similar to other services offered by MORSE, LINKS has a user-friendly interface with information separated into broad categories to allow users to sort and search based…
The MORSE KEY: Upcoming Events and Conferences There are a number of conferences/events/deadlines that individuals in market access may be interested in for the upcoming month of September. For more details, please visit the MORSE Key Market Access Events page. Government/Agencies September 15 – CADTH Deadline for Comments on Therapeutic Review Framework September 18 – PMPRB HDAP Meeting September 20 –CDEC Meeting Associations September 11 – 2017 CAPDM MEMBER…
Health Technology Assessment Panel On Tuesday, June 13, 2017, the Canadian Association for Healthcare Reimbursement (CAHR) held the Market Access 201 conference in Toronto. The theme for this conference was Parallel or Intersecting Paths, the Future of Public and Private Reimbursement in Canada which consisted of five fascinating panels focusing on key topics of interest to the Canadian pharmaceutical stakeholders. Over the coming weeks, MORSE will be releasing summaries…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
HTA | MORSE Consulting Inc.
